Examples of using Trabectedin in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
This reconstituted solution contains 0.05 mg/ml of trabectedin.
One ml of reconstituted solution contains 0.05 mg of trabectedin.
Trabectedin was administered as a 24-hour intravenous infusion every 21 days.
The excretion of trabectedin in milk has not been studied in animals.
Myelosupression and hepatoxicity were identified as the primary toxicity for trabectedin.
The concomitant use of trabectedin with alcohol must be avoided see section 4.5.
1 mg of trabectedin.
The safety and efficacy of trabectedin in paediatric patients have not yet been established.
The effects of trabectedin on cardiovascular and respiratory function have been investigated in vivo anesthetised Cynomolgus monkeys.
Each vial containing 0.25 mg of trabectedin is reconstituted with 5 ml of water for injections.
Concomitant use of trabectedin with phenytoin may reduce phenytoin absorption leading to an exacerbation of convulsions.
Trabectedin must not be used in patients with creatinine clearance<
Concomitant use of trabectedin with phenytoin may reduce phenytoin absorption leading to an exacerbation of convulsions.
Based on its known mechanism of action, trabectedin may cause serious birth defects when administered during pregnancy.
In a placebo-controlled QT/QTc study, trabectedin did not prolong the QTc interval in patients with advanced solid malignancies.
If trabectedin is used at the end of pregnancy,
Trabectedin binds to the minor groove of deoxyribonucleic acid(DNA),
The patients received the trabectedin dose of 1.2 mg/m2 recommended for Japanese patients 1.2 mg/m2 once every 3 weeks q3wk 24-h.
close monitoring of toxicities are required and dose reductions of trabectedin should be considered.
Alcohol consumption must be avoided during treatment with trabectedin due to the hepatotoxicity of the medicinal product see section 4.4.